Nusinersen (SPINRAZA®), delivered by intrathecal injection, is an antisense oligonucleotide targeting the SMN2 gene and has been approved for the treatment of both adult and pediatric populations with SMA [22, 23]. Here, SMN2 is linked to proximal spinal muscular atrophy.